In a previous study involving the MCA tumor model, immunotherapy with the single epitope p53158-166 peptide-based vaccine, p53 V1, was found to have limited efficacy due to vaccine-induced immunoselection of epitope loss variants and tumor escape [36]. Here, TP53 is linked to neoplasm.